#United States #Elk Grove Village #Ionis Pharmaceuticals #Orsini Pharmacy #DAWNZERA

Orsini's Exclusive Collaboration with Ionis Pharmaceuticals for DAWNZERA™

Orsini, a recognized leader in pharmacy solutions for rare diseases, has made significant strides by becoming the exclusive specialty pharmacy partner for Ionis Pharmaceuticals and their newly approved medication, DAWNZERA™ (donidalorsen). This FDA-approved drug is a proactive treatment for hereditary angioedema (HAE), a potentially life-threatening genetic condition characterized by recurrent and severe swelling attacks.

Understanding Hereditary Angioedema (HAE)

Hereditary angioedema is a rare but serious condition affecting approximately 7,000 individuals in the U.S. Patients experience unpredictable episodes of swelling that can impact various body parts, including the face, throat, and stomach. While trauma or stress can sometimes trigger these attacks, often there is no identifiable cause. The urgency in treating HAE is paramount, as severe swelling can lead to dangerous obstructions, particularly in the throat, making immediate access to effective medication a necessity for patients.

DAWNZERA offers new hope to adults and pediatric patients aged 12 and older by allowing them to self-administer the drug via a subcutaneous auto-injector. The innovative mechanism of action for DAWNZERA involves reducing the production of prekallikrein, a protein that is instrumental in the mechanism of HAE attacks.

Orsini's Commitment to Patients

Darin DeCarlo, the Chief Commercial Officer at Orsini, expressed pride in the collaboration with Ionis, emphasizing their long-standing commitment to providing exceptional care and support for HAE patients. Orsini has been at the forefront of HAE care for over 14 years, and this partnership reinforces the mutual dedication of both organizations to improve patient outcomes in the HAE community.

In its pursuit to offer comprehensive care to patients with rare diseases, Orsini also strives to facilitate enhanced access to advanced therapies. Through their pharmacy distribution channels, patient services, and clinical management, they ensure that patients receive a streamlined experience when accessing revolutionary treatments.

The company's operating philosophy, encapsulated in their slogan "No Patient is Left Behind™," illustrates their commitment to delivering high-touch, personalized care to every individual they serve.

Orsini’s dedication is validated by their numerous accreditations, including designations as a Rare Disease Pharmacy Center of Excellence and distinctions in rare diseases and orphan drugs from The Accreditation Commission for Health Care (ACHC). These accreditations not only ensure high standards in patient care but also reinforce Orsini's reputation as a leading provider in the pharmacy sector for rare diseases.

Conclusion

This collaboration between Orsini and Ionis Pharmaceuticals signifies a crucial advancement in the management of hereditary angioedema. With the integration of DAWNZERA into Orsini's comprehensive portfolio, the future appears promising for those affected by HAE. As this partnership evolves, Orsini continues to uphold its mission of transforming the lives of patients and families impacted by rare diseases, ensuring they receive access to the innovative therapies that they desperately need.